305 related articles for article (PubMed ID: 30599112)
21. An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans.
Guzman MA; Rugel AR; Tarpley RS; Alwan SN; Chevalier FD; Kovalskyy DP; Cao X; Holloway SP; Anderson TJC; Taylor AB; McHardy SF; LoVerde PT
PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008517. PubMed ID: 32810153
[TBL] [Abstract][Full Text] [Related]
22. Molecular basis for hycanthone drug action in schistosome parasites.
Guzman M; Rugel A; Tarpley RS; Cao X; McHardy SF; LoVerde PT; Taylor AB
Mol Biochem Parasitol; 2020 Mar; 236():111257. PubMed ID: 32027942
[TBL] [Abstract][Full Text] [Related]
23. [Research progress of the evaluation methods on the resistance of schistosome to praziquantel].
Guo J; Guo JG
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2005 Jun; 23(3):182-4. PubMed ID: 16300016
[No Abstract] [Full Text] [Related]
24. Dandelion (Taraxacum officinale) Improves the Therapeutic Efficiency of Praziquantel in Experimental Schistosomiasis.
Atwa MTM; Abd-Elrazek AM; Salem NIS
Acta Parasitol; 2022 Jun; 67(2):773-783. PubMed ID: 35067863
[TBL] [Abstract][Full Text] [Related]
25. Resistance of Schistosoma mansoni to praziquantel: is there a problem?
Doenhoff MJ; Kusel JR; Coles GC; Cioli D
Trans R Soc Trop Med Hyg; 2002; 96(5):465-9. PubMed ID: 12474468
[TBL] [Abstract][Full Text] [Related]
26. Liposomal-praziquantel: efficacy against Schistosoma mansoni in a preclinical assay.
Frezza TF; Gremião MP; Zanotti-Magalhães EM; Magalhães LA; de Souza AL; Allegretti SM
Acta Trop; 2013 Oct; 128(1):70-5. PubMed ID: 23811113
[TBL] [Abstract][Full Text] [Related]
27. Schistosomiasis then and now: what has changed in the last 100 years?
Wilson RA
Parasitology; 2020 Apr; 147(5):507-515. PubMed ID: 31965953
[TBL] [Abstract][Full Text] [Related]
28. Effect of preventive chemotherapy with praziquantel on schistosomiasis among school-aged children in sub-Saharan Africa: a spatiotemporal modelling study.
Kokaliaris C; Garba A; Matuska M; Bronzan RN; Colley DG; Dorkenoo AM; Ekpo UF; Fleming FM; French MD; Kabore A; Mbonigaba JB; Midzi N; Mwinzi PNM; N'Goran EK; Polo MR; Sacko M; Tchuem Tchuenté LA; Tukahebwa EM; Uvon PA; Yang G; Wiesner L; Zhang Y; Utzinger J; Vounatsou P
Lancet Infect Dis; 2022 Jan; 22(1):136-149. PubMed ID: 34863336
[TBL] [Abstract][Full Text] [Related]
29. An adjuvant effect of Metformin as an anti-fibrotic agent when administered with the anti-schistosomal Praziquantel in Schistosoma mansoni infected mice.
Salama WM; El-Naggar SA; Harras SF; El-Said KS
Trop Biomed; 2021 Jun; 38(2):205-213. PubMed ID: 34172712
[TBL] [Abstract][Full Text] [Related]
30. Schistosomiasis elimination by 2020 or 2030?
Fenwick A; Jourdan P
Int J Parasitol; 2016 Jun; 46(7):385-8. PubMed ID: 26907938
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of prophylactic efficacy and safety of praziquantel-miltefosine nanocombination in experimental Schistosomiasis mansoni.
Eissa MM; El-Azzouni MZ; El-Khordagui LK; Abdel Bary A; El-Moslemany RM; Abdel Salam SA
Acta Trop; 2020 Dec; 212():105714. PubMed ID: 32950482
[TBL] [Abstract][Full Text] [Related]
32. Differential impact of mass and targeted praziquantel delivery on schistosomiasis control in school-aged children: A systematic review and meta-analysis.
Cribb DM; Clarke NE; Doi SAR; Vaz Nery S
PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007808. PubMed ID: 31603895
[TBL] [Abstract][Full Text] [Related]
33. Something old, something new: is praziquantel enough for schistosomiasis control?
Secor WE; Montgomery SP
Future Med Chem; 2015; 7(6):681-4. PubMed ID: 25996059
[No Abstract] [Full Text] [Related]
34.
Adekiya TA; Aruleba RT; Klein A; Fadaka AO
J Biomol Struct Dyn; 2022 May; 40(8):3697-3705. PubMed ID: 33225839
[TBL] [Abstract][Full Text] [Related]
35. Impact of treatment with a Protein Tyrosine Kinase Inhibitor (Genistein) on acute and chronic experimental Schistosoma mansoni infection.
Sobhy MMK; Mahmoud SS; El-Sayed SH; Rizk EMA; Raafat A; Negm MSI
Exp Parasitol; 2018 Feb; 185():115-123. PubMed ID: 29331278
[TBL] [Abstract][Full Text] [Related]
36. Praziquantel as the preferred treatment for schistosomiasis.
Condeng YH; Katu S; Aman AM; Rasyid H; Bakri S; Iskandar H
Int Marit Health; 2024; 75(1):49-54. PubMed ID: 38647059
[TBL] [Abstract][Full Text] [Related]
37. Evolution of schistosomiasis-induced pathology after therapy and interruption of exposure to schistosomes: a review of ultrasonographic studies.
Richter J
Acta Trop; 2000 Oct; 77(1):111-31. PubMed ID: 10996127
[TBL] [Abstract][Full Text] [Related]
38. Praziquantel for the treatment of schistosomiasis during human pregnancy.
Friedman JF; Olveda RM; Mirochnick MH; Bustinduy AL; Elliott AM
Bull World Health Organ; 2018 Jan; 96(1):59-65. PubMed ID: 29403101
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of Schistosoma mansoni infection and the therapeutic efficacy of praziquantel among school children in Manna District, Jimma Zone, southwest Ethiopia.
Bajiro M; Dana D; Ayana M; Emana D; Mekonnen Z; Zawdie B; Garbi A; Kure A; Zeynudin A
Parasit Vectors; 2016 Oct; 9(1):560. PubMed ID: 27772528
[TBL] [Abstract][Full Text] [Related]
40. Praziquantel: An update on the mechanism of its action against schistosomiasis and new therapeutic perspectives.
Nogueira RA; Lira MGS; Licá ICL; Frazão GCCG; Dos Santos VAF; Filho ACCM; Rodrigues JGM; Miranda GS; Carvalho RC; Nascimento FRF
Mol Biochem Parasitol; 2022 Nov; 252():111531. PubMed ID: 36375598
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
